MRKR · Marker Therapeutics, Inc.
Marker Therapeutics Inc (MRKR)
What's happening
- MRKR is down 2.14% today, trading at $1.15. — Live quote
- Volume today (2,185) is well below its 3-month average of 88,620. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.09 actual vs. $-0.22 estimated (+59.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $30.2M | $25.8M | $14.8M | $21.2M | $13.8M |
| P/E | -2.74 | -1.89 | -1.16 | -1.63 | -1.22 |
| Price/Book | 2.49 | 1.87 | 0.80 | 2.02 | 0.95 |
| ROE | -90.58% | -98.87% | -69.44% | -123.57% | -78.25% |
| ROA | -75.55% | -78.24% | -58.75% | -87.78% | -66.73% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +12.6%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-10-19; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -51.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -343.0%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MRKR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$2.6M | -$4.1M | -$2.1M | -$5.1M | -$5.0M | -$2.4M | -$2.3M | -$2.5M |
| Net income | -$1.8M | -$3.2M | -$2.0M | -$4.0M | -$4.4M | -$2.3M | -$2.2M | -$2.4M |
| EPS (diluted) | $-0.09 | $-0.16 | $-0.12 | $-0.29 | $-0.40 | $-0.26 | $-0.25 | $-0.27 |
| EPS (basic) | $-0.09 | $-0.16 | $-0.12 | $-0.29 | $-0.40 | $-0.26 | $-0.25 | $-0.27 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $14.6M | $17.4M | $19.1M | $21.7M | $14.8M | $17.0M | $22.0M | $10.9M |
| Total liabilities | $2.4M | $3.6M | $2.3M | $3.3M | $4.3M | $2.5M | $3.5M | $3.5M |
| Stockholders' equity | $12.2M | $13.8M | $16.8M | $18.4M | $10.5M | $14.5M | $18.6M | $7.4M |
| Total current assets | $14.6M | $17.4M | $19.1M | $21.7M | $14.8M | $17.0M | $22.0M | $10.9M |
| Total current liabilities | $2.4M | $3.6M | $2.3M | $3.3M | $4.3M | $2.5M | $3.5M | $3.5M |
| Cash & equivalents | $11.3M | $14.9M | $16.1M | $17.6M | $10.5M | $13.7M | $19.2M | $9.0M |
| Other current assets | $7.2K | $13.2K | — | — | — | — | $2.0K | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Accounts payable | $585.0K | $1.5M | $793.7K | $951.0K | $1.7M | $1.3M | $1.1M | $1.9M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | $974.8K | $1.4M | $1.4M | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | $804.8K | $1.0M | — | $328.3K | $656.6K | $411.3K | $1.7M | $903.4K |
| Common stock & paid-in capital | $16.7K | $16.7K | $16.7K | $16.7K | $11.3K | $11.2K | $10.7K | $8.9K |
| Retained earnings | -$464.2M | -$462.4M | -$459.2M | -$457.5M | -$455.5M | -$451.5M | -$447.0M | -$443.2M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.7M | -$1.4M | -$1.9M | -$2.7M | -$1.9M | -$5.5M | -$4.7M | $1.2M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | $0 | $9.9M | $100 | $505 | $14.9M | $1.7K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $195.7K | $178.4K | $111.1K | $33.3K | $14.0K | $379.1K | $50.5K | $53.3K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Operating income | -$12.9M | -$11.1M | -$14.6M | -$19.8M | -$39.5M |
| Net income | -$12.2M | -$10.7M | -$8.2M | -$29.9M | -$41.9M |
| EPS (diluted) | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 |
| EPS (basic) | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $19.1M | $22.0M | $17.1M | $34.4M | $68.1M |
| Total liabilities | $2.3M | $3.5M | $3.1M | $14.8M | $24.1M |
| Stockholders' equity | $16.8M | $18.6M | $14.1M | $19.6M | $44.0M |
| Total current assets | $19.1M | $22.0M | $17.1M | $16.6M | $46.0M |
| Total current liabilities | $2.3M | $3.5M | $3.1M | $7.8M | $12.9M |
| Cash & equivalents | $16.1M | $19.2M | $15.1M | $11.8M | $42.4M |
| Other current assets | — | $2.0K | — | — | — |
| Property, plant & equipment | — | — | — | $12.3M | $12.3M |
| Accounts payable | $793.7K | $1.1M | $961.0K | $1.1M | $5.1M |
| Accrued liabilities | — | — | — | — | $2.4M |
| Deferred revenue (current) | $974.8K | — | — | $0 | $1.1M |
| Short-term debt | — | — | — | — | — |
| Other current liabilities | — | $1.7M | $1.3M | — | — |
| Common stock & paid-in capital | $16.7K | $10.7K | $8.9K | $8.4K | $8.3K |
| Retained earnings | -$459.2M | -$447.0M | -$436.3M | -$428.0M | -$398.1M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.0M | -$10.9M | -$16.4M | -$27.0M | -$27.3M |
| Investing cash flow | — | — | $18.7M | -$4.9M | -$3.1M |
| Financing cash flow | $9.9M | $15.0M | $1.1M | $202.1K | $52.6M |
| Capital expenditures | — | — | — | — | — |
| Depreciation & amortization | — | — | — | $2.8M | $2.1M |
| Share-based compensation | $537.5K | $245.9K | $858.3K | $3.3M | $6.0M |
| Deferred income taxes | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Other financing activities | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MRKR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2021-03-16 to 2024-12-23
Recent transactions
- Most recent: ELMS STEVE (Director) — Open market purchase of 11,085 shares on 2024-12-23.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| ELMS STEVE | Director | Open market purchase | 2024-12-23 | 11,085 |
| New Enterprise Associates 16, L.P. | Reporting person | Open market purchase | 2024-12-23 | 554,250 |
| Eansor Norman David | Director | Gift | 2021-03-25 | 14,285 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2024-12-23 | ELMS STEVE | Director | Open market purchase | 11,085 | $3.20 |
| 2024-12-23 | New Enterprise Associates 16, L.P. | Reporting person | Open market purchase | 554,250 | $3.20 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:50 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-19 | 8-K | 2026-10-19 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-04 | 8-K | 2026-05-01 | View on SEC.gov → |
| 2026-03-19 | 8-K | 2026-03-18 | View on SEC.gov → |
| 2026-03-18 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-02-09 | 8-K | 2026-02-09 | View on SEC.gov → |
| 2025-11-19 | 4 | 2025-11-17 | View on SEC.gov → |
| 2025-11-19 | 4 | 2025-11-17 | View on SEC.gov → |
| 2025-11-19 | 4 | 2025-11-17 | View on SEC.gov → |
| 2025-11-14 | 8-K | 2025-11-14 | View on SEC.gov → |
| 2025-11-13 | 10-Q | 2025-09-30 | View on SEC.gov → |
Recent news
Headlines about MRKR (Marker Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Marker Therapeutics receives $2.6M FDA grant for cancer study By Investing.com
Investing.com India · 2026-10-19 -
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
Yahoo · 2026-10-19 -
Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer
Benzinga · 2026-10-19 -
APP,RCAT,CCC,OPTU,INOD,MRKR,RNAC,OKLO,ARDX,AJG | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-17 -
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy
Yahoo · 2026-10-16 -
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2026-10-16 -
MRKR: MARKER THERAPEUTICS - Price & Consenus Chart
Zacks Investment Research · 2026-10-16 -
New Strong Buy Stocks for October 16th
Yahoo · 2026-10-16
No headlines in this category right now — try “All”.